Follow The Filings

CYTK Cytokinetics

Cytokinetics earnings company data as of 2:06 PM ET 10/30

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -1.41 — —
Rev $41.6M — —

Insider trades

Open-market buys and sales by CYTK's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CYTK insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $47.1M sold by 10 insiders under 10b5-1 plans
  1. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $224K 3,500 shares at $64.01 2.2% of stake
    Traded Oct 20 Filed Oct 20
    ↗
  2. Robert I Blum CEO
    Planned sale
    $472K 7,500 shares at $62.88 2.6% of stake
    Traded Oct 12 Filed Oct 13
    ↗
  3. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $215K 3,500 shares at $61.38 2.2% of stake
    Traded Oct 6 Filed Oct 6
    ↗
  4. Robert I Blum CEO
    Planned sale
    $491K 7,500 shares at $65.46 2.6% of stake
    Traded Sep 28 Filed Sep 28
    ↗
  5. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $239K 3,500 shares at $68.29 2.2% of stake
    Traded Sep 22 Filed Sep 22
    ↗
  6. Robert E Landry Director
    Planned sale
    $72K 1,000 shares at $72.13 11% of stake
    Traded Sep 15 Filed Sep 15
    ↗
  7. Robert I Blum CEO
    Planned sale
    $7.3M 105,426 shares at $69.62
    Traded Sep 14–15 Filed Sep 15
    ↗
  8. Robert E Landry Director
    Planned sale
    $75K 1,000 shares at $74.66 9.8% of stake
    Traded Sep 11 Filed Sep 11
    ↗
  9. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $264K 3,500 shares at $75.46 2.2% of stake
    Traded Sep 8 Filed Sep 8
    ↗
  10. B Lynne Parshall Director
    Planned sale
    $357K 5,000 shares at $71.48 32% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  11. Andrew Callos EVP, Chief Commercial Officer
    Planned sale
    $702K 10,000 shares at $70.24 15% of stake
    Traded Aug 31 Filed Aug 31
    ↗
  12. Robert I Blum CEO
    Planned sale
    $527K 7,500 shares at $70.24 1.9% of stake
    Traded Aug 31 Filed Aug 31
    ↗
  13. Fady Ibraham Malik EVP Research & Development
    Planned sale
    $265K 3,500 shares at $75.82 2.2% of stake
    Traded Aug 18 Filed Aug 18
    ↗
  14. Robert I Blum CEO
    Planned sale
    $576K 7,500 shares at $76.76 1.9% of stake
    Traded Aug 10 Filed Aug 10
    ↗
  15. Andrew Callos EVP, Chief Commercial Officer
    Planned sale
    $1.1M 14,000 shares at $79.88 19% of stake
    Traded Jul 30 Filed Jul 30
    ↗

Also filed in the last 12 months, not counted as buying or selling: 66 option exercises, 48 stock grants, 10 sales to cover taxes, 9 share withholdings for taxes, and 4 gifts.

SEC filings

Recent issuer filings from EDGAR, 6 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 10 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.